DOI QR코드

DOI QR Code

Efficacy and Toxicity of Gemcitabine Plus Docetaxel Combination as a Second Line Therapy for Patients with Advanced Stage Soft Tissue Sarcoma

  • Ali Osman, Kaya (Department of Medical Oncology, Bakirkoy Dr Sadi Konuk Training and Research Hospital) ;
  • Suleyman, Buyukberber (Department of Medical Oncology, Medical School, Gazi University) ;
  • Metin, Ozkan (Department of Medical Oncology, Medical School, Erciyes University) ;
  • Necati, Alkis (Department of Medical Oncology, Ankara Oncology Training and Research Hospital) ;
  • Alper, Sevinc (Department of Medical Oncology, Medical School, Gaziantep University) ;
  • Nuriye Yildirim, Ozdemir (Department of Medical Oncology, Ankara Numune Training and Research Hospital) ;
  • Suleyman, Alici (Department of Medical Oncology, Goztepe Medical Park Hospital) ;
  • Onur, Esbah (Department of Medical Oncology, Ankara Oncology Training and Research Hospital) ;
  • Veli, Berk (Department of Medical Oncology, Medical School, Erciyes University) ;
  • Celalettin, Camci (Department of Medical Oncology, Medical School, Gaziantep University) ;
  • Arife, Ulas (Department of Medical Oncology, Ankara Oncology Training and Research Hospital) ;
  • Ugur, Coskun (Department of Medical Oncology, Medical School, Gazi University) ;
  • Mustafa, Benekli (Department of Medical Oncology, Medical School, Gazi University)
  • Published : 2012.02.29

Abstract

Purpose: To assess the safety and efficacy of a gemcitabine plus docetaxel regimen as a second line therapy for patients with advanced soft tissue sarcoma (STS) resistant to doxorubicin and ifosfamide-based therapy. Patients and Methods: Medical records of 64 patients with advanced STS who received gemcitabine plus docetaxel regimen as a second line treatment between May 2006 and June 2011 were examined. All patients had been previously treated with doxorubicin plus ifosfamide-based regimen at first line setting. Patients received gemcitabine 900 $mg/m^2$ on days one and eight intravenously over 90 minutes, followed by docetaxel 75 $mg/m^2$ on day eight intravenously over one hour. Cycles were repeated every 3 weeks. Results: The male-to-female ratio was 37/27 and the median age was 44 years (range; 19-67 years). Objective responses were observed in 13 (20.3 %) patients (2 CR, 11 PR) and stable disease in 21 (32.8 %). Total clinical benefit (CR+PR+SD) was observed in 34 (53.1 %). Median overall survival (OS) was 18 months (95% confidence interval (CI):12.1-23.9) and Median time to progression (TTP) was 4.8 months (95% CI: 3.6-6). A total of 243 cycles of chemotherapy were administered. The median number of cycle was 3 (range;1-11). The most common grade 3-4 hematologic toxicity was neutropenia (35.9 %). The most common nonhematologic toxicities consisted of nausea/vomiting (37.5 %), mucositis (32.8 %), peripheral neuropathy (29.7%), and fatigue (26 %). There was no toxicity-related death. Conclusion: The combination of gemcitabine plus docetaxel is an active and tolerable regimen as a second line therapy for patients with advanced soft tissue sarcoma who have failed doxorubicin and ifosfamide-based therapy.

Keywords

Gemcitabine;docetaxel;advanced soft tissue sarcoma;second line therapy;Turkey

References

  1. Bay JO, Ray-Coquard I, Fayette J, et al; Groupe Sarcome Français (2006). Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer, 119, 706-11. https://doi.org/10.1002/ijc.21867
  2. Edmonson JH, Ryan LM, Blum RH,et al (1993). Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol, 11, 1269-75. https://doi.org/10.1200/JCO.1993.11.7.1269
  3. Hartmann JT, Oechsle K, Huober J, et al (2006). An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs, 24, 249-53. https://doi.org/10.1007/s10637-005-3537-1
  4. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988). Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-Darabinofuranosylcytosine. Cancer Res, 48, 4024-31.
  5. Hensley ML, Blessing JA, Degeest K, et al (2008). Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol, 109, 323-8. https://doi.org/10.1016/j.ygyno.2008.02.024
  6. Hensley ML, Maki R, Venkatraman E, et al (2002). Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol, 20,2824-31. https://doi.org/10.1200/JCO.2002.11.050
  7. Iwasaki H, Huang P, Keating MJ, Plunkett W (1997). Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood, 90, 270-8.
  8. Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics, 2006. CA Cancer J Clin, 56, 106-30. https://doi.org/10.3322/canjclin.56.2.106
  9. Le Cesne A, Judson I, Crowther D, et al (2000). Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colonystimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol, 18, 2676-84. https://doi.org/10.1200/JCO.2000.18.14.2676
  10. Leu KM, Ostruszka LJ, Shewach D, et al (2004). Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol, 22, 1706-12. https://doi.org/10.1200/JCO.2004.08.043
  11. Maki RG (2007). Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist, 12, 999-1006. https://doi.org/10.1634/theoncologist.12-8-999
  12. Maki RG, Wathen JK, Patel SR, et al (2007). Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol, 25, 2755-63. https://doi.org/10.1200/JCO.2006.10.4117
  13. Maurel J, López-Pousa A, de Las Peñas R, et al (2009). Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol, 27, 1893-8. https://doi.org/10.1200/JCO.2008.19.2930
  14. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG (1992). Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol, 19, 646-62.
  15. Santoro A, Tursz T, Mouridsen H, et al (1995). Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol, 13, 1537-45. https://doi.org/10.1200/JCO.1995.13.7.1537
  16. Schiff PB, Fant J, Horwitz SB (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-7. https://doi.org/10.1038/277665a0
  17. Schütte J, Mouridsen HT, Stewart W, et al (1990). Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer, 26, 558-61. https://doi.org/10.1016/0277-5379(90)90075-5
  18. van Hoesel QG, Verweij J, Catimel G, et al (1994). Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol, 5, 539-42. https://doi.org/10.1093/oxfordjournals.annonc.a058909
  19. Verweij J, Lee SM, Ruka W, et al (2000). Randomized phase II study of docetaxel versus doxorubicin in first- and secondline chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol, 18, 2081-6. https://doi.org/10.1200/JCO.2000.18.10.2081

Cited by

  1. Emerging therapies for adult soft tissue sarcoma vol.14, pp.6, 2014, https://doi.org/10.1586/14737140.2014.885840
  2. Computed Tomography Manifestations of Histologic Subtypes of Retroperitoneal Liposarcoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6041
  3. Associations of chemo- and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma vol.34, pp.1, 2015, https://doi.org/10.1186/s13046-015-0175-0
  4. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients vol.14, pp.1, 2016, https://doi.org/10.1186/s12957-016-1059-2
  5. Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study vol.50, pp.1, 2018, https://doi.org/10.4143/crt.2016.535
  6. First-Line Therapy for Metastatic Soft Tissue Sarcoma vol.20, pp.1, 2019, https://doi.org/10.1007/s11864-019-0606-9